StreetAlpha.app
Home › Stocks › PTN

Palatin Technologies Inc (PTN)

$4.58
▼ −7.10%
LAST CLOSE · NOV 20

Palatin is a New Jersey biopharmaceutical company developing peptide and small molecule medicines that target melanocortin receptors. It last closed at $4.58 on Nov 20, down 7.10% on the day. For the quarter ended Sep 2026, PTN reported EPS of -$1.29 on revenue of $361,802, with revenue down 95.9% from a year ago. Over the last 12 months PTN insiders bought $0 of stock on the open market and sold $9K, according to SEC Form 4 filings.

AI Auto Pilots
Is PTN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PTN.

Key Stats

Last 12 months
Results
Revenue
$4.7M
−46.9% vs a year ago
Net income
−$18.1M
−385.4% margin
EPS (diluted)
−$8.51
Operating margin
−392.2%
−$18.4M operating income
Valuation
Market cap
$8.2M
1.8M shares
P/E
–
No P/E while losing money
Price to sales
1.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$3.7M
At Sep 30
Shareholder equity
$2.0M
Shares outstanding
1.8M
At Nov 13
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2022: $1.5M$1.5MFY2022FY2023: $4.9M$4.9MFY2023FY2024: $4.5M$4.5MFY2024FY2025: $0$0FY2025FY2026: $13.2M$13.2MFY2026

From PTN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
—
No date on file yet
Reported EPS
-$1.29
Quarter ended Sep 2026
Year ago EPS
$4.26
−130.3% on a GAAP basis
Revenue
$361,802
−95.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$5.92Dec '24Mar 2025: -$9.13Mar '25Jun 2025: $1.74Jun '25Sep 2025: $4.26Sep '25Dec 2025: -$2.86Dec '25Mar 2026: -$0.37Mar '26Jun 2026: -$1.33Jun '26Sep 2026: -$1.29Sep '26Latest -$1.29
Revenue by quarter
Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $8.8MSep '25Dec 2025: $116,036Dec '25Mar 2026: $3.9MMar '26Jun 2026: $300,770Jun '26Sep 2026: $361,802Sep '26Latest $361,802
StreetAlpha's call on PTNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PTN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PTN

Technical Analysis

PTN · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 23% below its 20 day and 64% below its 50 day average. It is 189% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the 52 week low at $4.51, and the nearest resistance the Pivot at $4.73.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 15.0%/day
Key levels
$31.0052 week high+576.9%
$13.25200 day average+189.3%
$8.59100 day average+87.6%
$7.5050 day average+63.8%
$7.33Swing high (Nov 9)+60.0%
$5.6420 day average+23.1%
$4.89Pivot R1+6.8%
$4.73Pivot+3.3%
$4.58Last close
$4.5152 week low−1.5%
$4.51Swing low (Oct 28)−1.5%
$4.41Pivot S1−3.7%
Indicators
RSI (14)32.01Weak, oversold below 30Neutral
MACD-0.54Below its signal lineBearish
Stochastic7.5Near the bottom of its rangeOversold
ADX (14)25.4Trending down
Williams %R-99.3Oversold below −80, overbought above −20Oversold
CCI (20)-93.3Oversold below −100, overbought above 100Neutral
Rate of change−26.9%Change over 10 sessionsBearish
ATR (14)$0.69Typical daily range, 15.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PTN

What happened before

See how PTN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PTN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PTN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PTNHow many large options trades hit PTN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PTN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●10 buying vs 10 selling
  • ▲Held by funds +9.1 pts
  • ▲Funds holding +5
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3025+20.0%
In funds' top 1000–
Held by funds47.6%38.5%+9.1 pts
New / increased8 / 25 / 7−16.7%
Reduced / sold out7 / 36 / 5−9.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PTN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PTN Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$9K1 sale · 1 insider
100% of the selling was under pre-arranged trading plans.
2025-12 sold $9KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Dec 24, 2025Stephen T WillsExecutive VP and CFO/COOSale plan565$16.74$9K
May 7, 2025Robert K Deveer JrDirectorBuy100,000$0.10$10K
Every insider buy and sale for PTN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PTN insider trades →

From SEC Form 4 filings by PTN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PTN is in one of them and how their past PTN trades turned out.

PTN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PTN in an article yet. Here's the latest on the wider market.

About Palatin Technologies

Palatin is a biopharmaceutical company based in Cranbury, New Jersey. It develops drug candidates that act on the melanocortin receptor system, a group of receptors involved in inflammation, immune response, appetite and metabolism. Its main focus is treatments for obesity and rare diseases tied to this pathway, with other candidates aimed at eye, gut and immune conditions. The company generally works with pharmaceutical partners to license and commercialize its products.

Headquarters
Cranbury, NJ